Conference Coverage

Children with Down syndrome and ALL have good outcomes today


 

REPORTING FROM ASPHO 2018


For patients with standard-risk low disease, 5-year EFS was 100% for those with Down syndrome, compared with 95.35% for patients without. Respective rates for standard risk average and high disease were 88.07% vs. 89.63%. and 82.35% vs. 86.18%.

Down syndrome was not an independent risk factor for survival in multivariate analyses accounting for risk group, Dr. Maloney said.

COG AALL0331 was supported by the National Cancer Institute. Dr. Maloney reported having no financial disclosures.

SOURCE: Maloney K et al. ASPHO 2018, Abstract PP 2001.

Pages

Recommended Reading

Blinatumomab triggers complete MRD response in ALL
MDedge Hematology and Oncology
Relapse rate drives stem cell transplant failure in pediatric ALL patients
MDedge Hematology and Oncology
Cooperation can drive T-ALL, study shows
MDedge Hematology and Oncology
Drug receives orphan designation for ALL
MDedge Hematology and Oncology
Art education benefits blood cancer patients
MDedge Hematology and Oncology
Team uses iPSCs to create ‘universal’ CAR T cells
MDedge Hematology and Oncology
Study reveals gene variants that predispose kids to ALL
MDedge Hematology and Oncology
Gene variants linked to survival after HSCT
MDedge Hematology and Oncology
Health Canada approves product for adult ALL
MDedge Hematology and Oncology
Team maps genetic evolution of T-ALL subtype
MDedge Hematology and Oncology